Dr. Siddiqui is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
330 Brookline Ave
Boston, MA 02215Phone+1 617-667-7000
Education & Training
- Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 2015 - 2018
- Beth Israel Deaconess Medical CenterInternship, Internal Medicine, 2015 - 2016
- Yale School of MedicineClass of 2015
Certifications & Licensure
- FL State Medical License 2021 - Present
- AZ State Medical License 2023 - 2026
- TN State Medical License 2023 - 2026
- TX State Medical License 2019 - 2026
- WA State Medical License 2023 - 2026
- AL State Medical License 2023 - 2025
- GA State Medical License 2023 - 2025
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
- Join now to see all
Publications & Presentations
PubMed
- Hemophagocytic Lymphohistiocytosis (HLH) Following Immune Checkpoint Therapy (ICT).Saivaroon Gajagowni, Emily Wang, Jianbo Wang, Matthew T Campbell, Bilal A Siddiqui
Case Reports in Oncological Medicine. 2025-01-01 - Body composition in recurrent prostate cancer and the role of steroidogenic genotype.Neha Venkatesh, Rebecca S Tidwell, Yao Yu, Ana Aparicio, Amado J Zurita
Endocrine-Related Cancer. 2024-12-01 - Steroids in Immune Checkpoint Inhibitor Myocarditis.Nicolas L Palaskas, Bilal A Siddiqui, Anita Deswal
JACC. Cardiooncology. 2024-10-01
Press Mentions
- Cytokine Release Syndrome and Neurotoxicity After CAR T-cell TherapySeptember 20th, 2024
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: